Cerulean Pharma Inc. Doses First Patients in Randomized Phase 2 Clinical Study of CRLX101 in Non-Small Cell Lung Cancer

Published: Jul 12, 2011

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cerulean Pharma Inc., a leader in designing and developing tumor-targeted nanopharmaceuticals, today announced the dosing of the first patients with CRLX101 in a randomized, controlled non-small cell lung cancer (NSCLC) Phase 2 clinical trial.

Back to news